Business
Imutex Vaccine Phase I Study Results
Imutex Vaccine Phase I Study Results.
About this update from Hvivo Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8975S\n Open Orphan PLC\n 19 November 2021\n \n \n \n \n 19 November 2021\n \n \n Open Orphan plc\n \n \n (\"Open Orphan\" or the \"Company\")\n \n \n \n \n \n Imutex to present positive Phase I clinical study results for AGS-v PLUS mosquito vaccine candidate\n \n \n \n \n \n AGS-v PLUS mosquito vaccine candidate shows favourable safety, tolerability, and immunogenicity results\n \n \n Results to be presented at the American Society of Tropical Medicine and Hygiene Annual Meeting\n \n \n \n \n \n \n Open Orphan plc\n \n \n (AIM: ORPH) \n announces that data from the first-in-human Phase I clinical study evaluating the safety, immunogenicity, and in vitro efficacy of AGS-v PLUS, Imutex Limited's (\"Imutex') mosquito saliva vaccine candidate against arboviral diseases, as well as data on the candidate's effect on the reproductive capacity of mosquitoes that fed on vaccinated subjects will be presented on the 20th and 21st of November 2021. Imutex Limited (\"Imutex\") is a joint venture with PepTcell Limited (\"PepTcell\") (the legal name of SEEK Group) in which Open Orphan has a 49% shareholding. \n \n \n \n \n \n The results will be presented in two virtual sessions at the American Society of Tropical Medicine and Hygiene (\"ASTMH\") Annual Meeting, held from 17-21 November 2021. The titles and details of the two presentations are as follows:\n \n \n \n \n \n · \n \n \"Blood feeding on humans vaccinated with AGS-v PLUS, a mosquito salivary peptide vaccine, impairs the reproductive capacity of female Aedes albopictus mosquitoes\" - \n \n Scientific Session 91: Mosquitoes-Vector Biology Epidemiology I,\n at 8.00 am (ET) on 20 November 2021. To be presented by Joshua Lacsina, M.D., Ph.D. of the Laboratory of Malaria and Vector Research at the National Institute of Allergy and Infectious Diseases.\n \n \n · \n \n \"\n \n \n Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases\"\n \n - Scientific Session 126: \n Clinical Tropical Medicine: Vector borne Disease, at 8.00 am (ET) on 21 November 2021. To be presented by DeAnna J. Friedman-Klabanoff, M.D. of the University of Maryland School of Medicine. \n \n \n \n \n \n Following the presentations, Imutex expect to publish the results from the study in a scienti...